摘要
目的:通过比较毛细支气管炎患儿治疗前后血清IL-6,IL-8,TNF-α水平及肺功能的变化来评价孟鲁司特钠对毛细支气管炎的疗效。方法:将80例毛细支气管炎患儿随机分为试验组(n=40)与对照组(n=40),对照组仅给予常规治疗,试验组在常规治疗的基础上口服孟鲁司特钠治疗。采用酶联免疫吸附法检测毛细支气管炎患儿治疗前及治疗7 d后血清IL-6,IL-8,TNF-α水平。另外,分别于治疗前后对患儿进行肺功能tPTEF/tE,vPTEF/vE的检测,并进行临床评分。同时观察患儿喘鸣音及湿罗音消失的时间。结果:治疗后试验组患儿血清IL-6,IL-8,TNF-α水平较对照组显著降低,肺功能指标tPTEF/tE,vPTEF/vE较对照组显著升高,临床评分较对照组显著降低,喘鸣音及湿罗音消失时间较对照组显著缩短,差异均有统计学意义。结论:孟鲁司特钠能降低毛细支气管炎患儿血清炎性细胞因子的水平,减轻其炎症反应,使患儿的肺功能显著改善,临床症状体征减轻,是治疗毛细支气管炎的有效药物。
Objective： To compare changes in the levels of IL-6, IL-8 and TNF-αin serum, and the pulmonary functions before and after treatment with oral montelukast for evaluating the efficacy of montelukast on bronchiolitis. Methods： Totally 80 children with bronchiolitis were divided randomly into 2 groups （n = 40 in each group）. They were treated with oral montelukast ＋ conventional therapy or with conventional therapy alone （control）. The serum levels of IL-6, IL-8 and TNF-α were detected by enzyme-linked immunosorbent assay before and. after 7-day treatment. In addition, the parameters of pulmonary function, tPTEF/tE and vPTEF/vE, and the clinical scores were determined by pulmonary function instrument. In the same time, the disappearing time of wheezing and wet rale were collected. Results： After 7-day treatment, the serum levels of IL-6, IL-8 and TNF-αwere decreased in montelukast group significantly more than those in control group （t= -3. 361, P=0. 001 ; t =-4. 125, P=0. 000 ; t = - 2. 489, P = 0. 015 ）. The parameters of pulmonary function, tPTEF/tE and vPTEF/vE, were significantly higher in montelukast group than in control group （ t = 3. 365, and 2. 162 ; P = 0. 001, and 0. 034）. The clinical scores were decreased in montelukast group significantly more than in control group （t=- 3. 293, P = 0. 001 ）. The disappearing time of wheezing and wet rale was significantly shorter in montelukast group than in control group （t =- 2. 847,P =0. 006 ; t = - 2. 429, P = 0. 017）. Conclusion ： Montelukast is effective in the treatment of children with bronchiolitis. It can lower the sponse, improve the pulmonary function, and lessen inflammatory cytokines in serum, reduce the inflammatory reclinical symptoms and physical signs.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2011年第15期1439-1441,共3页
Chinese Journal of New Drugs
